Skip to main content

Eli Lilly — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

158
Companies
$7.3B
Total invested
$55.2M
Avg. check
17
Industries
Biotechnology 20Medical 10Health Care 9Therapeutics 8Biopharma 6Pharmaceutical 5+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 158
TRex Bio
November 2024

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

Bioinformatics · South San Francisco$84.0M Series B
AMPRION
September 2024

Amprion is a biotech company that focuses on the diagnosis for brain diseases.

Biotechnology · San Francisco$6.0M Series B
basys.ai
September 2024

Basys.ai automates the process of prior authorization and utilization management for health plans/payers using an AI-based platform.

Artificial Intelligence (AI) · Cambridge$25K Seed
NanoSyrinx
September 2024

NanoSyrinx is a discovery stage biotechnology company based at the University of Warwick's Medical School.

Biotechnology · Coventry$13.1M Series A
Superluminal Medicines
September 2024

Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.

Biotechnology · Boston$120.0M Series A
OrsoBio
September 2024

OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.

Biopharma · Palo Alto$67.0M Series B
RetiSpec
July 2024

RetiSpec is a medical imaging startup developing an eye scanner for early detection of Alzheimer's Disease pathology.

Health Care · Toronto$10.0M Series A
Myricx Bio
July 2024

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

Biotechnology · London$115.3M Series A
Vanqua Bio
July 2024

Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.

Biotechnology · Chicago$45.0M Venture - Series Unknown
Radar Therapeutics
May 2024

Radar Therapeutics pioneer in treatment modality, precision-expressed mRNA-based therapeutics.

Medical · Berkeley$13.4M Seed
Firefly Bio
February 2024

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Biotechnology · San Francisco$94.0M Series A
Prism BioLab
January 2024

Prism is a biotechnology company that develops therapeutic drugs that cure intractable diseases using unique peptide mimic technology.

Biopharma · Fujisawa$10.2M Series C
GenEdit
January 2024

GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.

Biotechnology · South San Francisco$24.0M Series A
Mariana Oncology
September 2023

Mariana Oncology is a biotechnology research industry.

Bioinformatics · Watertown$175.0M Series B
Nido Biosciences
May 2023

Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.

Biotechnology · Watertown$86.6M Series B
DiogenX
May 2023

DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.

Biotechnology · Marseille$36.8M Series A
InduPro
January 2026

InduPro deevlops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease.

Biotechnology · SeattleCorporate Round
Terns Pharmaceuticals
December 2025

Terns Pharmaceuticals develops small-molecule therapies for chronic diseases including cancer, metabolic disorders, and liver conditions.

Biotechnology · Foster City$650.0M Post-IPO Equity
Sanegene Bio
December 2025

Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.

Biopharma · Woburn$110.0M Series B
Excelsior Sciences
December 2025

Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.

Artificial Intelligence (AI) · New York$70.0M Series A
Amphista Therapeutics
December 2022

Amphista Therapeutics operates as a biopharmaceutical company.

Biopharma · CambridgeSeries B
Regor Therapeutics
December 2021

Regor Therapeutics is an international biotech company that focuses in the therapeutic areas of oncology, metabolic and autoimmune diseases.

Biotechnology · Boston$50.0M Venture - Series Unknown
Verve Therapeutics
November 2023

Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.

Biotechnology · Boston$143.8M Post-IPO Equity
Recludix Pharma
January 2026

Recludix pharma is a developing platform to treat cancer patients.

Biotechnology · San DiegoUndisclosed

Where Eli Lilly invests

Biotechnology20
Medical10
Health Care9
Therapeutics8
Biopharma6
Pharmaceutical5

About Eli Lilly's portfolio

How many companies has Eli Lilly invested in?

Eli Lilly has invested in 158 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Eli Lilly invest in?

Eli Lilly's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Biopharma. The firm invests across 17 different industry categories.

What is Eli Lilly's largest investment?

Among tracked funding rounds, Terns Pharmaceuticals received $650.0M in a Post-IPO Equity round. Eli Lilly's total known invested capital is $7.3B.

What is the average investment size for Eli Lilly?

Eli Lilly's average investment size is $55.2M across its portfolio of 158 companies.

What are Eli Lilly's most recent investments?

Recent Eli Lilly portfolio additions include TRex Bio, AMPRION, basys.ai, NanoSyrinx, Superluminal Medicines. These companies were founded in 2020 or later.

Reach the founders behind these 158 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →